Press coverage about Cyclacel Pharmaceuticals (NASDAQ:CYCC) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.78989583937 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
Cyclacel Pharmaceuticals (CYCC) traded down $0.10 during mid-day trading on Monday, hitting $1.90. 1,356,724 shares of the stock were exchanged, compared to its average volume of 576,066. Cyclacel Pharmaceuticals has a one year low of $1.50 and a one year high of $10.90.
WARNING: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/11/cyclacel-pharmaceuticals-cycc-receiving-somewhat-positive-media-coverage-analysis-finds.html.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.